P-MEC China, co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets,will take place at the Shanghai New International Expo Center (SNIEC) on 22-24 June 2020. The event will be co-located with CPhI China with total area exceeding 210,000m2 and over 75,000 visits of professionals are expected. P-MEC China unveiled as a co-locate of CPhI China with the rising

Polaryx Therapeutics, a biotech company developing patient-friendly small molecule therapeutics for lysosomal storage disorders announced today that the Company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of LINCL patients with PLX-200. Neuronal Ceroid Lipofuscinoses are a group of rare autosomal recessive neurodegenerative lysosomal storage disorders. Among them, LINCL is caused by mutations

Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, announced today that it has been granted an exclusive, worldwide sublicense by SATT Sud-Est to the immunoconjugates of the anti?CD146-ts antibody (excluding diagnosis), which binds a tumor-specific form of CD146 found on a number of solid cancers. CD146-ts has a central role in the mechanism of tumorige

ANI Pharmaceuticals, Inc. announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Potassium Citrate Extended-Release Tablets USP, 10 mEq and 15 mEq.  The current annual U.S. market for this product is approximately $75 million, according to IQVIA. Arthur S. Przybyl, ANI's President and CEO stated, "We are excited to receive FDA approval for this extended release drug that was s

Syntegon Technology is the new name among the market leaders in the processing and packaging industry. Known as Bosch Packaging Technology until late 2019, the former Bosch division today presented itself as an independent enterprise at the company headquarters inWaiblingen (Germany). Syntegon Technology’s business focus is on intelligent and sustainable technologies for the pharmaceutical and food industries. Extending the service range is a priority for the company. Syntegon Technolog

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets. Under the

Iovance Biotherapeutics, Inc., an advanced phase biotechnology company developing new T-cell based cancer immunotherapies, and Cellectis, a clinical phase biopharmaceutical company specializing in the development of immunotherapies based on genetically modified allogeneic CAR-T cells (UCART), have announced the signing of a research partnership and an exclusive global license agreement granting at Iovance a license for certain applications of Cellectis TALEN® technology to develop tumor i

Empirico Inc. announced today that it has entered into a strategic collaboration with Ionis Pharmaceuticals. During the three-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis’ industry-leading antisense technology. Under the terms of the agreement, Ionis can advance up to ten tar

Aro Biotherapeutics Company announces it has entered a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, through which Ionis will use Aro’s CENTYRIN™ technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs). Under the terms of the agreement, the companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically

AXIM® Biotechnologies, Inc., a world leader in cannabinoid research and development, announced today that the Company has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”) as a wholly-owned subsidiary. AXIM and Sapphire intend to enter into Definitive Documents for the transaction no later than February 28, 2020. However, the binding Term Sheet will remain in full force and effect until such t